For Sun Pharma’s Dilip Shanghvi, specialty drugs remain the magic bullet
Specialty drugs are fast becoming a lucrative market globally. And India’s largest drugmaker has done well to make the most of this opportunity so far. But it’s too soon to rest easy.
1 August, 2024•10 min
0
1 August, 2024•10 min
0
More in Business
Business
Has Devyani International turned a corner?
There’s something for both pessimists and optimists in the QSR player’s Q3 results. Right now, it looks like a coin toss where this business will go next, which makes the euphoric market reaction seem out of place.
You may also like
Business
The weight-loss wave that’s changing India—one sector at a time
Mounjaro’s blockbuster debut has already sparked a seismic shift across Indian healthcare, diagnostics and pharma. A marked change in consumer behaviour looks imminent.
Business
Dr. Reddy’s wants to be India’s fifth largest drugmaker. What will it take?
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
Health
Indian pharma exporters protesting against new regulations is not a good look
The rules require exporters of certain drugs to get an NOC from importing countries—a small but much-needed step to restoring India’s credibility in the global pharma market.
